Key result
De novo loss-of-function KCNJ2 mutations (p.Arg82Trp and p.Pro186Gln) were identified in two patients with atypical Andersen-Tawil Syndrome presenting as CPVT, acting as dominant negatives to drastically reduce Kir2.1 channel activity.
Why the study?
When extracardiac symptoms of Andersen-Tawil Syndrome are atypical or absent, patients can be misdiagnosed with CPVT, where beta blockers may be less efficient.
Case Report (n=2)
Yes
Identification of KCNJ2 loss-of-function mutations in patients with CPVT-like phenotypes highlights the importance of including KCNJ2 in CPVT genetic screening panels to guide appropriate therapy.
Supports KCNJ2 evaluation in atypical CPVT; extends Andersen-Tawil spectrum but leaves screening panel changes hypothesis-generating.
Andersen-Tawil Syndrome (ATS) is a rare disease defined by the association of cardiac arrhythmias, periodic paralysis and dysmorphic features, and is caused by KCNJ2 loss-of-function mutations. However, when extracardiac symptoms are atypical or absent, the patient can be diagnosed with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), a rare arrhythmia at high risk of sudden death, mostly due to RYR2 mutations. The identification of KCNJ2 variants in CPVT suspicion is very rare but important because beta blockers, the cornerstone of CPVT therapy, could be less efficient. We report here the cases of two patients addressed for CPVT-like phenotypes. Genetic investigations led to the identification of p. Arg82Trp and p. Pro186Gln de novo variants in the KCNJ2 gene . Functional studies showed that both variants forms of Kir2.1 monomers act as dominant negative and drastically reduced the activity of the tetrameric channel. We characterize here a new pathogenic variant (p.Pro186Gln) of KCNJ2 gene and highlight the interest of accurate cardiologic evaluation and of attention to extracardiac signs to distinguish CPVT from atypical ATS, and guide therapeutic decisions. We also confirm that the KCNJ2 gene must be investigated during CPVT molecular analysis.
No takes yet. Share an insight, caveat, or question.
Tanno et al. (2021) conducted a case report in Atypical Andersen-Tawil Syndrome / Catecholaminergic Polymorphic Ventricular Tachycardia (n=2). KCNJ2 loss-of-function mutations (p.Arg82Trp and p.Pro186Gln) vs. Wild-type KCNJ2 was evaluated on Kir2.1 channel activity. De novo loss-of-function KCNJ2 mutations (p.Arg82Trp and p.Pro186Gln) were identified in two patients with atypical Andersen-Tawil Syndrome presenting as CPVT, acting as dominant negatives to drastically reduce Kir2.1 channel activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: